Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial
复制标题
DOI：
10.1001/archpsyc.64.6.633
复制
发表时间：
2007-06-01
影响因子：
--
通讯作者：
Lieberman, Jcffrey A.
中科院分区：
文献类型：
--
作者：
Keefe, Richard S. E.;Bilder, Robert M.;Lieberman, Jcffrey A.
背景：精神分裂症患者的神经认知功能损害是严重的，是功能结局的重要预测因子。第二代（非典型）抗精神病药物和较老药物对神经认知的相对影响尚未全面确定。治疗2个月后神经认知综合评分的变化。次要结果包括持续治疗后6个月和18个月的神经认知综合评分变化以及神经认知领域的变化。目的：比较几种第二代抗精神病药和第一代抗精神病药奋乃静的神经认知作用。设计：在分配接受奥氮平、奋乃静、富马酸奎替鲁胺、或利培酮长达18个月，如Lieberman等人先前报道的。盐酸齐拉西酮在获得食品和药物管理局批准后被纳入。设置：57个地点参与，包括学术地点和代表社区的治疗精神卫生设施。患者：从一个队列的1460例患者在治疗研究中，817完成神经认知测试之前立即随机化，然后经过2个月的treatment.Main结果的措施：主要结果是在2个月的治疗后的神经认知综合评分的变化。次要结果包括继续治疗后6个月和18个月的神经认知综合评分变化以及神经认知领域的变化。
Context: Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains.Objective: To compare the neurocognitive effects of several second-generation antipsychotics and a first-generation antipsychotic, perphenazine.Design: Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al. Ziprasidone hydrochloride was included after its approval by the Food and Drug Administration.Setting: Fifty-seven sites participated, including academic sites and treatment mental health facilities representative of the community.Patients: From a cohort of 1460 patients in t he treatment study, 817 completed neurocognitive testing immediately prior to randomization and then after 2 months of treatment.Main Outcome Measures: The primary outcome was change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains.Results: At 2 months, treatment resulted in small neurocognitive improvements of z=0.13 for olanzapine (P